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In tuberous sclerosis (TSC)–associated tumors, mutations in the TSC genes lead to aberrant activation of the
mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway. mTORC1 signaling impacts many
biological processes including the epithelial-mesenchymal transition (EMT), which is suggested to promote tumor
progression and metastasis in various types of cancer. In this study, we report hybrid cells with epithelial and
mesenchymal features in angiomyolipomas and partial EMT in carcinomas from TSC patients and describe a new
model of EMT activation during tumor progression from cyst to papillary adenoma to solid carcinoma in the
kidneys of Tsc2+/− mice. Features of EMT occurred infrequently in TSC-associated cysts but increased as the
lesions progressed through papillary adenoma to solid carcinoma where epithelial-mesenchymal hybrid cells were
abundant, indicating partial EMT. We also compared the effects of the novel ATP-competitive mTOR inhibitor
AZD2014 with the allosteric mTOR inhibitor rapamycin on EMT and tumor burden. Both AZD2014 and rapamycin
potently suppressed EMT of renal tumors and effectively blocked tumor progression in Tsc2+/− mice. These
results suggest that partial EMT is a shared feature of TSC-associated renal tumors in humans and mice and
occurs during TSC-associated tumor progression. EMT-related signaling pathways may represent therapeutic
targets for tumors associated with mutations in the TSC genes.
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Tuberous sclerosis (TSC) is a tumor syndrome caused by mutations
of the TSC1 or TSC2 gene [1]. Kidney lesions are one of the most
frequent manifestations of TSC, with angiomyolipomas (AMLs)
being the most common lesions. Despite the fact that most AMLs are
benign tumors, their propensity for spontaneous hemorrhage can
have life-threatening consequences. Other TSC-associated kidney
lesions include oncocytoma, malignant AML, and renal cell
carcinoma (RCC) [2–4]. RCC occurs in about 4% of TSC patients
and is characterized by diagnosis at a young age and pathological
heterogeneity with clear-cell, papillary, and chromophobe carcinoma
subtypes. TSC-associated lesions are also observed in other organs
including lymphangioleiomyomatosis (LAM) affecting the lungs,
subependymal giant cell astrocytomas in the brain, cardiac
rhabdomyomas, and facial angiofibromas. Mice heterozygous for
Tsc1+/− or Tsc2+/− develop small cystic lesions in the kidneys
detectable histologically from as early as 2 months. With aging, thenumber and size of lesions increase, and they progress to papillary and
then solid malignancies, providing a valuable model for investigating
mechanisms underlying tumor progression [5–8]. Human and mouse
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second allele and aberrant activation of the mechanistic target of
rapamycin complex 1 (mTORC1) signaling pathway [5,6,9,10].
mTORC1 plays a crucial role in the control of many biological
activities such as cell growth, proliferation, and survival [11]. mTORC1
is also an important regulator of epithelial-mesenchymal transition
(EMT) [12]. EMT is a cellular process that converts epithelial cells into
cells with a mesenchymal phenotype and is coordinated by complex
regulatory networks involving transcriptional control and epigenetic
modifications [13,14]. EMT is critical for embryogenesis and is also
implicated in wound healing and pathogenesis of disease. Activation of
EMT is suggested to promote tumor initiation, progression, metastasis,
and resistance to chemotherapy and immunotherapy in various types of
cancer including renal cell carcinoma [15–17].
TSC-associated AML and LAM are associated with markers of
EMT, although their cellular origin remains to be established [18,19].
The mesenchymal marker vimentin is also detected in some TSC-
associated RCC, suggesting EMT [3]. AMLs shrink significantly in
response to treatment with the allosteric mTOR inhibitor rapamycin
and its derivatives [20–23], but the responses are partial, and tumors
usually regrow after treatment withdrawal. Partial resistance to
rapamycin or its derivatives is probably associated with loss of negative
feedback regulation that leads to activation of AKT [24]. AZD2014,
also known as vistusertib, is a novel ATP-competitive dual inhibitor
of mTORC1 and mTORC2 and has shown dramatic suppression of
EMT in hepatoma cells with significant antitumor effects in various
cancer cell lines and xenograft mouse models of cancer [25–28].
In this study, we report hybrid cells with epithelial and
mesenchymal features in AML and partial EMT in renal carcinomas
from TSC patients and describe a new model of EMT activation
during tumor progression in the kidneys of Tsc2+/− mice. We have
also demonstrated that both AZD2014 and rapamycin effectively
suppress EMT and block tumor progression. These results suggest
that EMT-related signaling pathways may provide targets for treating
tumors associated with mutations in the TSC genes.
Materials and Methods
Animal Procedures
Animal procedures were performed in accordance with the UK
Home Office guidelines and approved by the Ethical Review Group
of Cardiff University. As described previously, Tsc2+/− mice were
backcrossed to balb/c strain [6]. To determine the effect of AZD2014
and rapamycin on EMT and molecular signaling and to compare the
antitumor efficacy of AZD2014 with rapamycin, Tsc2+/− litter mates
were randomly allocated into 3 groups of 8, balanced for gender.
Animals were treated with vehicle, AZD2014 (20 mg/kg, maximum
tolerated dose), and rapamycin (5 mg/kg) for 2 months from the age
of 14 months through intraperitoneal injection 5 times a week. At the
end of treatment, animals were humanely killed for assessment of
tumor burden and analysis of protein expression and phosphorylation
in normal tissues and tumor samples. AZD2014 (APExBIO,
Houston, TX) at 4 mg/ml and rapamycin (LC Laboratories, Woburn,
MA) at 1 mg/ml were prepared in vehicle solution (2.5% PEG-400,
2.5% Tween-80, and 2.5% DMSO) respectively.
Histology
Assessment of tumor burden in the kidneys of mice was performed
as described previously [8]. Mouse kidneys were fixed in 10%buffered formalin saline for 24 hours, processed, and paraffin
embedded. Six coronal sections of 5 μm were prepared at a
200-μm interval from both kidneys of each mouse, stained with
hematoxylin/eosin, and scanned using an Aperio system (http://www.
aperio.com/?gclid = CNXN-8by4a UCFcINfAods3eg1w). Scanned
images were used for lesion quantification using ImageJ (http://
rsbweb.nih.gov/ij). Lesion number was determined, and maximum
cross-sectional whole area including noncellular spaces and cellular
area of each renal lesion were measured. Tumor burdens were
estimated from whole areas and cellular areas of all lesions (cystic,
papillary, and solid), cystic/papillary lesions, and solid carcinomas,
respectively. The assessment was conducted blindly with respect to
treatment status.
Immunohistochemistry (IHC)
This study was approved by the Institutional Review Board of the
Brigham and Women's Hospital, Boston MA. Human tumor
sections and mouse kidney sections were prepared as described
above. Conventional IHC was performed as described previously
[29]. Multiple sequential IHC (MS-IHC) was performed to
colocalize multiple antigens in the same cells. A crucial step of MS-
IHC was to completely strip previous primary antibodies to ensure
efficiency and specificity of subsequent primary antibody-antigen
reactions. The protocol used for stripping primary antibodies was
modified from Kim et al. [30]. For MS-IHC, previous IHC-stained
slides were incubated in xylene for 10 minutes to remove coverslips
and then incubated at 50°C in a buffered solution containing 5%
SDS, 0.5% mercaptoethanol, and 50 mm Tris–HCl (pH 7.5) for
60 minutes to strip primary antibodies, and finally, the protocol was
followed for conventional IHC. SignalStain Boost Rabbit specific
IHC Detection Reagent (Cell Signaling Technology, Danvers, MA)
and ImmPACT NovaRED Peroxidase Substrate or ImmPACT VIP
Peroxidase (HRP) Substrate (Vector Laboratories, Peterborough,
UK) were used to stain antigens according to the kit suppliers'
instruction. IHC or MS-IHC stained slides were scanned to generate
virtual slides for photo capture using an Aperio system. Primary
antibodies were used for IHC against phosphorylated S6 ribosomal
protein at S235/236, phosphorylated Akt at S473, E-cadherin,
vimentin, FSP1, α-SMA (Cell Signaling Technology, Danvers, MA),
Ki67, and active caspase 3 (Abcam, Cambridge, UK).
Western blot
Western blot was performed as described previously [29]. Protein
extracts were prepared from normal tissues and tumor samples using
AllPrep DNA/RNA/Protein Mini Kit (QIAGEN Ltd-UK, Crawley,
UK). Proteins were purified according to the kit supplier's
instruction. Twenty micrograms of protein per sample was separated
on NuPAGE 4%-12% Bis-Tris Gels (Fisher Scientific UK Ltd.,
Loughborough, UK) and transferred onto Amersham Protran
Premium 0.2- or 0.45-μm nitrocellulose blotting membranes (GE
Healthcare UK Ltd., Little Chalfont, UK). Blots were analyzed with
ECL Select Western Detection Kit (GE Healthcare UK Ltd.), and
signals were detected using Autochemi Imaging System (UVP,
Upland, CA). Horseradish peroxidise–conjugated secondary antibody
against rabbit was used for Western blot (Cell Signaling Technology).
Primary antibodies were used for Western blot against phosphory-
lated S6 ribosomal protein at S235/236, 4E-BP1 at T37/46, Akt at
S473, Akt at T308, and E-cadherin, vimentin, β-actin (Cell Signaling
Technology), phosphorylated PKC at T638 (Abcam);
Figure 1. mTOR signaling and protein levels of epithelial and mesenchymal markers in renal lesions of TSC patients.Tumor sections
prepared from TSC patients were used for MS-IHC. The same tumor sections were subjected to three rounds of IHC to sequentially detect
three indicated antigens. Higher-power views of boxed areas are presented next to the corresponding lower-power images. Black lines
are scale bars.(A) mTOR signaling in TSC-associated tumors. Representative IHC-stained sections were presented to show
phosphorylation of S6 at S235/236, Akt at S473, and PKC at T638.(B) Expression of epithelial and mesenchymal markers in TSC-
associated tumors. Representative IHC-stained sections were presented to show protein levels of E-cadherin, vimentin, and FSP1. Circled
areas show examples of tumor cells co-expressing E-cadherin and vimentin/FSP1.
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S2481 (Sigma-Aldrich, Dorset, UK).
Statistical Analysis
The Mann-Whitney test was used to compare tumor burden
between treatment groups. Two-tailed Fisher's exact test was used to
compare protein expression in tumor cells obtained by IHC between
treatment groups. P b .05 was considered to be statistically
significant. Analyses were performed using GraphPad Prism 7.03.
Results
Expression of Epithelial and Mesenchymal Markers in Kidney
Tumors of TSC patients and Tsc2+/- Mice
We examined mTOR signaling and markers of epithelial and
mesenchymal status in AML and RCC of TSC patients using MS-
IHC. The MS-IHC technique was validated using mouse kidney
sections as depicted in Supplementary Figure 1. Both mTORC1 and
mTORC2 were activated in these human tumors as evidenced by
increased phosphorylation of S6, Akt, and PKCα (Figure 1A). E-
cadherin was used as an epithelial marker, whereas vimentin, FSP1,
and α-SMA were used as mesenchymal markers. As shown in Figure
1B, vimentin and FSP1 were consistently detected in human tumors
as observed previously [31], while E-cadherin expression was alsoobserved. Co-expression of E-cadherin and vimentin/FSP1 was
observed in these tumors, indicating partial EMT in RCC and
existence of hybrid cells with epithelial and mesenchymal features in
AML (Figure 1B, Supplementary Figures 2 and 3). We then
investigated mTOR signaling and EMT in renal lesions of Tsc2+/−
mice using IHC on consecutive kidney sections. As reported
previously [7], both mTORC1 and mTORC2 were activated in all
renal lesions including cysts, papillary lesions, and solid malignancies
as indicated by increased phosphorylation of S6 and Akt (Figure 2A).
As shown in Figure 2A, E-cadherin was expressed in nearly all tumor
cells of cystic and papillary lesions, but expression was lower, variable,
and sometimes absent in tumor cells of carcinomas. In contrast, the
expression of vimentin, FSP1, and α-SMA was minimal in cysts but
increased in more advanced lesions (Figure 2, A and B). The IHC
images from consecutive kidney sections as depicted in Figure 2A
show co-expression of both epithelial and mesenchymal markers in
tumor cells, suggesting partial EMT [15].To confirm this observa-
tion, MS-IHC was performed on the same kidney sections. Many
hybrid epithelial-mesenchymal tumor cells were present as evidenced
by co-expression of E-cadherin, vimentin, and FSP1 (Figure 2C,
Supplementary Figures 4, 5, 5-1 and 5-2). These results suggest that
partial EMT in TSC-associated renal tumors is a shared feature by
human and mouse and that activation of EMT increases as tumors
progress from cysts to papillary adenomas and solid carcinomas.
Figure 2.mTOR signaling and protein levels of epithelial and mesenchymal markers in renal lesions of Tsc2+/− mice.(A) mTOR signaling
and expression of E-cadherin, vimentin, FSP1, and α-SMA. Adjacent kidney sections prepared from 16-month-old Tsc2+/−mice were used
for IHC. Representative IHC-stained sections were presented to show phosphorylation of S6 at S235/236 and Akt at S473, and protein
levels of E-cadherin, vimentin, FSP1, and α-SMA in different types of renal tumors from cystic/papillary lesions to solid malignancies.
Black arrows point to tumor cells stained by vimentin, FSP1, or α-SMA in cystic/papillary lesions. Black lines are scale bars.(B) Expression
of vimentin. Kidney sections prepared from 16-month-old Tsc2+/− mice were used for IHC. Representative IHC-stained sections were
presented to show different types of renal tumors negative (−) or positive (+) for vimentin. Higher-power views of boxed areas are
presented next to the corresponding lower-power images. Black lines are scale bars.(C) Identification of tumor cells with partial EMT.
Kidney sections prepared from 16-month-old Tsc2+/− mice were used for MS-IHC. The same kidney sections were subjected to three
rounds of IHC to sequentially detect three indicated antigens. Representative images were presented to show examples of tumor cells
co-expressing E-cadherin and vimentin/FSP1 in circled areas. Higher-power views of boxed areas are presented next to the corresponding
lower-power images. Around 60.1% (11.6%-96.8%) of tumor cells co-expressed E-cadherin and vimentin (and or FSP1) as estimated from
10 mouse renal carcinomas. Black lines are scale bars.
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Tumors of Tsc2+/- Mice
We then asked if mTOR inhibitors suppress EMT in renal lesions.
We first determined that the maximum tolerated dose of AZD2014
in Tsc2+/− mice was 20 mg/kg body weight per day via intraperitoneal
injection in a pilot study of 2 weeks of treatment. Three groups of
eight randomly allocated Tsc2+/− mice were then treated for 2
months, beginning at age 14 months, with vehicle, AZD2014
(20 mg/kg), or rapamycin (5 mg/kg) via intraperitoneal injection.
Following treatment, we examined protein levels of E-cadherin,
vimentin, and FSP1 by IHC on kidney sections. We found that the
protein levels of vimentin and FSP1 were significantly attenuated in
cystic/papillary lesions treated by AZD2014 or rapamycin compared
to vehicle (Figure 3). The proportion of cystic/papillary lesions with
one or more tumor cells positive for either vimentin or FSP1 was also
significantly reduced after treatment by AZD2014 or rapamycin
(Figure 3, Supplementary Tables 1 and 2). Furthermore, the protein
levels of both vimentin and FSP1 were dramatically reduced in solidcarcinomas treated by AZD2014 or rapamycin compared to vehicle
(Figure 4A), while the E-cadherin level was variable. Protein samples
were also prepared from solid carcinomas after treatment for Western
analysis. Consistently, Western analysis also demonstrated reduced
vimentin and variable E-cadherin levels in solid carcinomas treated by
AZD2014 or rapamycin compared to vehicle (Figure 4B). These
findings suggest that both AZD2014 and rapamycin suppress EMT
in most renal tumors of Tsc2+/− mice. However, in one large solid
carcinoma from a Tsc2+/− mouse treated with AZD2014, protein
levels of vimentin and FSP1 were not significantly affected, which
were consistent with phosphorylation levels of S6 and Akt
(Supplementary Figure 6), suggesting resistance to AZD2014.
Inhibition of mTORC1 and mTORC2 by AZD2014 and
Rapamycin in Renal Tumors of Tsc2+/- Mice
We performed IHC and Western analysis to determine the effects
of AZD2014 and rapamycin on mTOR signaling using kidney
sections and protein samples prepared from solid carcinomas, as
Figure 3. Effect of AZD2014 and rapamycin on EMT in cystic/papillary lesions of Tsc2+/− mice.(A) Kidney sections prepared from 16-
month-old Tsc2+/−mice treated with vehicle, AZD2014, or rapamycin were used to analyze vimentin by IHC. Upper panel: Representative
IHC-stained sections were presented to show protein levels of vimentin in tumor cells of cystic/papillary lesions. Black arrows point to
tumor cells with detectable vimentin as shown in boxed areas. Black lines are scale bars. Bottom panel: Proportion of cystic/papillary
lesions with cells positive for vimentin was shown from different treatment groups. For detailed statistical analysis, see Supplementary
Tables 1 and 2.(B) Kidney sections prepared from 16-month-old Tsc2+/− mice treated with vehicle, AZD2014, or rapamycin were used to
analyze FSP1 by IHC. Upper panel: Representative IHC-stained sections were presented to show protein levels of FSP1 in tumor cells of
cystic/papillary lesions. Black arrows point to tumor cells with detectable FSP1 as shown in boxed areas. Black lines are scale bars.
Bottom panel: Proportion of cystic/papillary lesions with cells positive for FSP1 was shown from different treatment groups.
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236, and 4E-BP1 at T37/46 was used as readouts of mTORC1
activity, and phosphorylation of mTOR at S2481, Akt at S473 and
T450, PKCα at T638, and the Akt substrate MDM2 at S166 was
used as readouts of mTORC2 activity. As expected, AZD2014
markedly reduced phosphorylation of all mTORC1 and mTORC2
markers in all renal tumors and normal kidneys (Figure 5,
Supplementary Figure 7). AZD2014 also reduced phosphorylation
of Akt at T308 (Figure 5B). Rapamycin significantly reduced
phosphorylation of all mTORC1 markers in all renal tumors and
normal kidneys (Figure 5, Supplementary Figure 7). In addition,
rapamycin clearly decreased phosphorylation of mTOR at S2481,
PKCα at T638, and MDM2 at S166 in solid tumors (Figure 5) and
of mTOR at S2481, and Akt at S473 and T450 in normal kidney
tissues (Supplementary Figure 7), but effects of rapamycin on
phosphorylation of Akt at T308 and S473 appeared to be variable in
solid carcinomas (Figure 5). As expected, increased phosphorylation
of Akt at S473 was also observed in some cystic lesions treated by
rapamycin (Figure 5A) as described previously [29], while other
lesions did not show evidence of rapamycin-induced increase in
phosphorylation of Akt at S473. These results indicate thatAZD2014 potently inhibited mTORC1 and mTORC2, while
rapamycin inhibited mTORC1 potently but partially inhibited
mTORC2 in renal tumors.
Effective blocking of Tumor Progression by AZD2014 and
Rapamycin in the kidneys of Tsc2+/- Mice
Both AZD2014 and rapamycin strikingly inhibited proliferation of
tumor cells in the kidneys of Tsc2+/− mice, but no significant changes
in apoptosis were detected with either drug given individually
(Supplementary Figure 8). We therefore sought to compare the
antitumor efficacy of AZD2014 with rapamycin in Tsc2+/− mice.
Animals treated for 2 months as described above were used for tumor
burden assessment. All animals survived until termination of
treatment, and no animals showed significant weight loss or other
observable clinical signs. Tumor burden was determined by analyzing
all lesions (cystic/papillary/solid), cystic/papillary lesions, and solid
carcinomas in the kidneys, respectively. Both AZD2014 and
rapamycin significantly reduced the total number (P = .0012; P =
.0002), size (P = .0047; P = .0047), and cellular area (P = .0047;
P = .0002) of all lesions (Figure 6, Supplementary Table 3).
Similarly, both AZD2014 and rapamycin significantly reduced the
Figure 4. Effect of AZD2014 and rapamycin on EMT in solid tumors of Tsc2+/− mice.(A) IHC analysis. Adjacent kidney sections prepared
from 16-month-old Tsc2+/− mice treated with vehicle, AZD2014, or rapamycin were used to analyze EMT by IHC. Representative IHC-
stained images were presented to show protein levels of vimentin, FSP1, and C-cadherin in solid tumors. Black lines are scale bars.(B)
Western blot analysis. Proteins were prepared from solid carcinomas dissected from Tsc2+/− mice treated for 2 months from the age of
14 months with vehicle, AZD2014, or rapamycin. Beta-actin was used as a loading control. Representative Western blots were presented
to show expression levels of vimentin and E-cadherin.
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P = .0148) of cystic/papillary lesions (Figure 6, Supplementary
Table 4). AZD2014 significantly reduced the total size of cystic/Figure 5. Effect of AZD2014 and rapamycin on mTORC1 and mTORC
sections prepared from 16-month-old Tsc2+/− mice treated with
Representative IHC-stained sections were presented to show phos
tumors. Black lines are scale bars.(B) Western blot analysis. Proteins
treated for 2 months from the age of 14 months with vehicle, AZ
Representative Western blots were presented to show phosphorylatio
Akt at T308 and S473, PKCα at T638, and MDM2 at S166.papillary lesions (P = .0019). Rapamycin also appeared to reduce the
total size of cystic/papillary lesions but not statistically significant
(P = .5737). Further, both AZD2014 and rapamycin significantly2 in renal tumors of Tsc2+/− mice.(A) IHC analysis. Adjacent kidney
vehicle, AZD2014, or rapamycin were used for IHC analysis.
phorylation of mTOR at S6 at S235/236 and Akt at S473 in renal
were prepared from solid carcinomas dissected from Tsc2+/−mice
D2014, or rapamycin. Beta-actin was used as a loading control.
n of mTOR at S2448 and S2481, S6 at S235/236, 4E-BP1 at T37/46,
Figure 6. Efficacy of AZD2014 and rapamycin on renal tumors in Tsc2+/− mice.Tsc2+/− mice were treated from 14 months old for
2 months (n = 8 each group). Dosages are described in methods. After treatment, kidney sections were prepared for histological
assessment of treatment efficacy. Left panel: comparison of total number and size (area) as well as cellular area of all lesions (cystic,
papillary and solid). Middle panel: comparison of total number and size (area) as well as cellular area of cystic/papillary lesions. Right
panel: comparison of total number and size (area) as well as cellular area of solid carcinomas. Horizontal bars indicate a median. For
detailed statistical analysis, see Supplementary Tables 3–5.
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.0002), and cellular area (P = .0095; P = .0002) of solid carcinomas
(Figure 6, Supplementary Table 5). No significant difference in
antitumor efficacy was found between AZD2014 and rapamycin.
These results indicate that both AZD2014 and rapamycin effectively
block tumor progression in the kidneys of Tsc2+/− mice.Discussion
We examined epithelial and mesenchymal markers in renal tumors
from TSC patients and Tsc2+/− mice. We observed partial EMT in
TSC-RCC, and hybrid cells with epithelial and mesenchymal features
in AML from TSC patients. EMT in sporadic RCC has been
associated with poor prognosis [32], and vimentin expression was
previously reported in TSC-associated RCC [3]. TSC-associated renal
AML and pulmonary LAM cells are considered to be mesenchymal
tumors, but their origin remains to be established. EMT has been
suggested to contribute to the pathogenesis of these lesions [18,19,33]
. Our findings in TSC-associated human tumors are consistent with
these observations. We also found that features consistent with partialEMT developed during tumor progression from cysts to papillary
adenomas and solid carcinomas in Tsc2+/− mice. Partial EMT, but
not necessarily complete EMT, is implicated in tumor progression
and metastasis, and tumor cells undergoing partial EMT appear to
have some attributes of cancer stem cells [15,16,34–38]. The hybrid
or intermediate epithelial-mesenchymal states of partial EMT
observed in circulating tumor cells of cancer patients may confer
plasticity and facilitate reverse mesenchymal-epithelial transition that
is required for metastatic colonization [37].
Until recently, most EMT-related studies to improve our
understanding of the mechanisms underlying tumor progression
and metastasis were performed in cultured tumor cells or in xenograft
tumor models. In a transgenic mouse model of pancreatic cancer, the
intermediate epithelial-mesenchymal states were determined by
lineage tracking through a Pdx1-Cre; RosaYFP system in premalignant
lesions and circulating pancreatic epithelial cells with attributes of
cancer stem cells [34]. Recently, several studies have also used lineage
tracking to determine EMT status to assess the roles of EMT-
inducing transcription factors in tumor progression and metastasis in
transgenic mouse models. These studies suggested that the
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to therapy depends on tumor type and tissue origin [39–41] . In the
current study, we used MS-IHC to directly characterize individual
tumor cells that co-express epithelial and mesenchymal markers
during tumor progression, from cystic lesions to papillary adenomas
and solid carcinomas, in the kidneys of Tsc2+/− mice. Based on our
data, we propose a new model of EMT activation during tumor
progression.
Most tumors in patients with TSC are benign (and often classified
as hamartomas). Nonetheless, malignant and metastatic variants of
TSC-associated RCC and malignant AML can develop, and a
metastatic mechanism also appears to be involved in the pathogenesis
in TSC2-associated pulmonary LAM [42]. Lung metastasis can occur
from renal cancers in Tsc1+/− mice, while there is little evidence of
metastatic disease from renal tumors in Tsc2+/− mice [5]. It may be
interesting, therefore, to investigate the relationship of EMT to LAM
[33] and to tumor progression and lung metastasis in Tsc1+/− mice.
We and others previously reported that rapamycin and ATP-
competitive PI3K/mTOR dual inhibitors such as GSK2126458 and
NVP-BEZ235 are effective for treating renal tumors in Tsc2+/− mice
[29,43]. In the current study, we compared the therapeutic efficacy of
AZD2014 (an ATP-competitive dual inhibitor of mTORC1/
mTORC2) and rapamycin for renal tumors in these mice and
found that both agents effectively reduced tumor burden. As
expected, AZD2014 consistently inhibited both mTORC1 and
mTORC2, while rapamycin strongly inhibited mTORC1 but
exhibited only a partial inhibitory effect on mTORC2 [27–29].
Tumor cells insensitive to rapamycin were reported to be sensitive to
AZD2014 in vitro [44,45]. AZD2014 also enhanced the radiosen-
sitivity of glioblastoma stem-like cells in vitro and in vivo in a
preclinical study [46]. In a xenograft mouse model of renal
carcinoma, AZD2014 was reported to be a more effective treatment
than rapamycin [28]. In contrast, we did not observe any superiority
of AZD2014 over rapamycin in antitumor efficacy, possibly reflecting
differences in tumor types and model systems. In a first-in-human
pharmacokinetic and pharmacodynamic study, partial responses to
AZD2014 were seen in a patient with pancreatic cancer and a patient
with breast cancer [47]. However, a recent randomized phase 2
clinical trial suggested that AZD2014 was not as effective as
everolimus (a rapamycin derivative) for VEGF-refractory metastatic
clear cell renal cancer [48]. Combination of AZD2014 with other
antitumor agents may improve therapeutic efficacy as described in
preclinical models of various malignancies [49]. Over 20 clinical trials
of cancer treatment have been initiated using combination therapy of
AZD2014 with other antitumor agents in the last year (https://
clinicaltrials.gov/ct2/results?cond=azd2014&term=&cntry1=
&state1=&recrs=). To date, there are no reports of treatment of TSC
patients using ATP-competitive PI3K/mTOR inhibitors, but a
clinical trial has recently been planned to treat patients with TSC1/
2 mutated refractory solid cancers using AZD2014 (https://www.
findmecure.com/clinicaltrials/show/nct03166176). Considering the
promising but partial response of TSC-associated tumors to
rapamycin or its derivatives [20–23], further studies are warranted
to compare the therapeutic efficacy of AZD2014 with rapamycin or
its derivatives in clinical settings.
In conclusion, we have established that both AZD2014 and
rapamycin suppress EMT and reduce the burden of all types of renal
tumors in Tsc2+/− mice. We identified only a single large solid tumor
that was resistant to AZD2014. Suppression of EMT may contributeto the antitumor efficacy of these agents for TSC-associated tumors.
Liao et al. reported that both AZD2014 and rapamycin suppressed
EMT in hepatoma cells, with AZD2014 having stronger effects [26].
Torin 1 (another ATP-competitive mTORC1/mTORC2 inhibitor)
and rapamycin also suppressed EMT in glioblastoma cells [50]. EMT
is activated and controlled through multiple complex regulatory
networks in tumors [13,14]. Targeting these networks in combina-
tion with mTOR inhibition may provide opportunities for the
therapy of refractory tumor types and eradication of cancer stem cells.
Further studies are required for the full dissection of the signaling
pathways involved in EMT in TSC-associated tumors, including
further investigation of TGFβ signaling, a potent driver of EMT and
tumor progression.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2019.05.003.
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